As we all know Butchah69 is committing suicide on Wednesday. I just don't know how to take this. We already lost him once last season but now this time we know it's for real. Just take a gun and shoot me too butchah I can't live without you 😞
A comprehensive reference for androgenetic alopecia — from DHT biology to stem cell regeneration
Before you can evaluate any treatment — current or experimental — you need to understand the mechanism driving androgenetic alopecia (AGA). The broad strokes are well-known, but the details matter.
The primary driver of male pattern baldness is dihydrotestosterone (DHT), a potent androgen derived from testosterone through the action of the enzyme 5-alpha reductase (5-AR). Two isoforms of this enzyme are relevant: Type 1, found predominantly in the skin and sebaceous glands, and Type 2, found in the hair follicle dermal papilla and the prostate. DHT binds to androgen receptors (AR) in the dermal papilla cells of genetically susceptible follicles. This binding triggers a cascade of changes in gene expression that progressively miniaturizes the follicle over successive hair cycles.
Miniaturization is not binary destruction — it is a gradual shortening of the anagen (growth) phase and a progressive reduction in the diameter of the hair shaft. A follicle that once produced a thick, terminal hair producing years of growth begins producing progressively thinner vellus hairs with shorter growth phases. Eventually, in advanced AGA, the follicle may become so miniaturized that it produces hairs invisible to the naked eye — but in most cases, the follicle itself remains alive and potentially reactive to treatment. This distinction is crucial: a follicle is functionally dormant, not necessarily dead.
The expression and sensitivity of androgen receptors in the scalp follicle is primarily genetically determined. The androgen receptor gene (AR) is located on the X chromosome, which is why maternal family history has historically been considered the dominant predictor. However, the genetics of AGA are polygenic — dozens of genetic loci contribute, including genes on autosomes. This means you can develop significant AGA with no bald relatives, and conversely, men with extensively bald fathers sometimes retain most of their hair.
The key insight is that DHT is necessary but not sufficient for AGA. Men with 5-alpha reductase deficiency do not develop AGA. However, most men with AGA have entirely normal circulating DHT levels — the issue is follicle-level sensitivity, not systemic androgen excess.
More recent research has refined the picture further. Hair follicle stem cells (HFSCs) reside in a niche called the bulge region of the follicle. In healthy hair cycling, HFSCs are periodically activated to drive the anagen phase. In AGA, these stem cells are not destroyed — they persist in the bulge — but they become progressively less able to transition from a quiescent to an activated state. The mechanisms include both direct androgen signaling and downstream suppression of activating pathways (including Wnt/β-catenin signaling). This HFSC activation failure is what the newest generation of experimental treatments — PP405, ET-02 — are designed to address at its root.
A frequently underappreciated factor in AGA is perifollicular inflammation and fibrosis. Chronic low-grade inflammation around the follicle, driven in part by sebum accumulation, microbial colonization (particularly Malassezia), and androgen-driven inflammatory signaling, leads to progressive collagen deposition around the follicle. This fibrosis further impairs follicle function and may contribute to irreversibility in advanced cases. It is one reason that treatments targeting sebum production and scalp inflammation — including ketoconazole shampoos — are thought to have adjunct benefit beyond their antifungal activity.
Clinically, male AGA is staged using the Hamilton-Norwood scale, which provides a seven-stage classification from no hair loss (Type I) to near-complete vertex and frontal loss connected by a single remaining band of parietal hair (Type VII). The scale is an imperfect but practical tool.
What the scale tells you:
One critical clinical point: Norwood staging describes the current pattern, not the endpoint. Most men who begin losing hair in their late teens or early twenties will progress along the scale over decades. Early, aggressive intervention during stages II–III offers the best return.
Minoxidil is the oldest and most widely used hair loss treatment, having been FDA-approved for topical use in men since 1988 (5% solution) and women (2% solution). It was discovered as a hair growth agent serendipitously — it was originally developed as an oral antihypertensive, and patients taking it orally noticed significant hypertrichosis.
Mechanism: Minoxidil is a potassium channel opener. In the scalp, it appears to work by prolonging the anagen phase, improving follicular vasodilation, and stimulating dermal papilla cells directly. The precise molecular mechanism remains incompletely understood — a meaningful admission given how long it's been in use. Minoxidil requires conversion to its active sulfated form by sulfotransferase enzymes present in the scalp. Approximately 30–40% of people are poor responders because they have insufficient scalp sulfotransferase activity.
Efficacy: In placebo-controlled trials, 5% topical minoxidil produces statistically significant increases in hair count and weight in the majority of users. The effect is primarily stabilization with moderate regrowth, predominantly of miniaturized follicles. It does not meaningfully address the androgen-mediated miniaturization driving the disease. The result is a treatment that holds ground rather than wins it.
Clinical response timeframe: No visible response for the first three to four months. Maximum benefit typically reached around 12–18 months of continuous use.
Side effects: Topical minoxidil is generally well-tolerated. The most common side effects are scalp irritation, dryness, and contact dermatitis — particularly with the propylene glycol vehicle in the solution formulation (the foam formulation avoids propylene glycol and tends to be better tolerated). Initial shedding in the first 4–8 weeks of use is common and represents the follicle cycle being disrupted and reset — it is not a sign of worsening loss, but it alarms a significant proportion of new users.
Forms: 2% and 5% solution; 5% foam. Available over the counter. Compounded formulations at higher concentrations (7%, 10%) are available but have less clinical evidence.
Low-dose oral minoxidil (LDOM) represents one of the more significant clinical shifts in AGA management over the past decade. Though technically an off-label use, it has accumulated a substantial evidence base and is increasingly used in dermatological practice.
Why low-dose: At antihypertensive doses (10–40 mg daily), oral minoxidil causes significant fluid retention, reflex tachycardia, and pericardial effusion risk. At the doses used for AGA — typically 0.625–2.5 mg daily in women, 1.25–5 mg daily in men — these cardiovascular effects are minimal in otherwise healthy individuals, though they are not zero.
Efficacy advantage: Because oral minoxidil bypasses the sulfotransferase bottleneck at the scalp (systemic absorption delivers active drug regardless of local enzyme activity), it is effective in individuals who are poor responders to topical minoxidil. It also addresses hair loss at all body sites, not just the application area, which is relevant in cases of diffuse thinning beyond the standard vertex/frontal pattern.
Side effects: The most commonly reported side effect is hypertrichosis — unwanted hair growth on the face, limbs, and body. This is less common at the lower doses used in AGA, but it affects a meaningful minority of users, particularly women. Fluid retention (mild lower extremity edema) and mild orthostatic hypotension can occur. Baseline cardiovascular assessment is appropriate, particularly in individuals with pre-existing cardiac disease.
Oral finasteride at 1 mg/day is the most efficacious pharmacological treatment for male AGA in the evidence base. It was FDA-approved for AGA in 1997. It selectively inhibits Type 2 5-alpha reductase, reducing serum DHT by approximately 70% and scalp DHT by a similar margin.
Efficacy: In the pivotal trials, finasteride 1 mg daily produced a statistically significant increase in hair count at two years versus placebo, with continued benefit at five years of follow-up. The benefit is most pronounced at the vertex; it is less consistently demonstrated at the anterior hairline. In practice, clinical experience supports meaningful benefit at all affected sites, though individual responses vary considerably.
Long-term use: Finasteride requires indefinite continuation. The benefit achieved is maintained as long as the drug is taken; discontinuation results in loss of retained and regrown hair within roughly 6–12 months. This is one of the more important facts to communicate to patients before initiating.
Side effects: The sexual side effect profile of oral finasteride has been extensively studied and remains a legitimate clinical concern, though the framing around it requires precision. In the pivotal trials, sexual dysfunction (decreased libido, erectile dysfunction, ejaculatory disorder) was reported in approximately 3.8% of the finasteride group versus 2.1% of the placebo group — a real but modest difference. The vast majority of side effects resolve upon discontinuation.
The more difficult question involves post-finasteride syndrome (PFS) — a reported condition in a subset of users in which sexual, neurological, and psychological symptoms persist after discontinuation. The existence and mechanism of PFS remains scientifically contested. Large epidemiological studies have not consistently supported the claimed incidence rates in advocacy literature, but individual cases of prolonged persistent symptoms appear to be real. This uncertainty is worth acknowledging honestly: the risk of persistent side effects is probably low but is not zero, and the honest position is that no confident quantification is currently possible.
Who to caution: Men with pre-existing sexual dysfunction, a history of depression, or significant health anxiety around sexual function warrant especially careful counseling before initiating finasteride.
Dutasteride inhibits both Type 1 and Type 2 5-alpha reductase, producing scalp DHT reduction of approximately 90%+ versus finasteride's ~70%. It was FDA-approved for benign prostatic hyperplasia (BPH) and is used off-label for AGA, though it received formal approval for AGA in South Korea and Japan.
Efficacy vs. finasteride: Direct head-to-head trials demonstrate dutasteride's superiority in hair count and hair weight outcomes. The difference is real but not dramatic in most clinical populations. Its longer half-life (several weeks vs. finasteride's several hours) means that missing doses is less consequential and that complete clearance after discontinuation takes longer.
Side effects: The side effect profile is qualitatively similar to finasteride but potentially more pronounced given deeper DHT suppression. Because of its longer half-life, any side effects that do occur may persist longer after discontinuation. Finasteride remains the preferred first-line choice in most cases for this reason, with dutasteride reserved for non-responders or patients who have tolerated finasteride well and wish to maximize suppression.
The most significant advance in practical AGA treatment over the past several years has been the mainstream adoption of compounded topical finasteride/minoxidil combinations delivered as a spray or serum. These products exploit the complementary mechanisms of both drugs while substantially reducing systemic finasteride exposure.
Pharmacokinetic rationale: Topical finasteride delivers drug to the scalp where it is needed while limiting systemic absorption. Studies have found that serum finasteride concentrations are more than 100 times lower with topical delivery compared to oral dosing at equivalent scalp DHT reduction. This dramatically reduces the side effect risk profile while maintaining meaningful efficacy.
Evidence: Multiple randomized controlled trials have demonstrated that topical finasteride/minoxidil combinations are superior to either agent alone. A 2023 study in men in their 20s showed the combination spray (5% minoxidil, 0.25% finasteride) outperformed monotherapy with either agent. Real-world data from a large telehealth platform analyzing over 638,000 patients found that 80.4% reported satisfaction with treatment, with only 2.7% reporting side effects — a favorable profile consistent with the reduced systemic exposure expected with topical delivery.
Current formulations: Compounded preparations available through telehealth platforms and compounding pharmacies typically include finasteride concentrations of 0.1–0.3% combined with minoxidil concentrations of 5–7%. Some formulations add ketoconazole and/or biotin. These are not FDA-approved as combined products (though both actives are individually approved), and they exist in the compounded drug regulatory space.
For most patients, particularly those hesitant about oral finasteride's side effect profile, a topical combination represents the current best practical starting point for pharmacological AGA treatment.
Platelet-rich plasma therapy involves drawing the patient's blood, centrifuging it to concentrate platelets and growth factors, and injecting this concentrate into the scalp. The theoretical basis is that platelet-derived growth factors (PDGF, VEGF, IGF-1) stimulate follicular activity.
The evidence base for PRP is heterogeneous. Multiple small randomized trials show statistically significant benefits over placebo, and head-to-head comparisons with minoxidil generally show comparable efficacy. However, the field lacks standardization — platelet concentrations, preparation protocols, injection depth, and frequency vary enormously across studies and providers. A 2019 systematic review in the Journal of the American Academy of Dermatology concluded that PRP shows promise but that the evidence quality is insufficient for a definitive efficacy recommendation.
In practice, PRP is best viewed as a useful adjunct to pharmacological therapy rather than a standalone treatment. It is expensive (typically $500–$1,500 per session), must be repeated (usually three sessions in the first year, then maintenance), and not covered by insurance.
Dermaroller or automated microneedling of the scalp (using needles of 0.5–1.5mm depth) induces a controlled wound-healing response and appears to enhance follicular penetration of topically applied treatments. Multiple small trials show additive benefit when microneedling is combined with minoxidil, and some data suggest synergy with finasteride as well. The proposed mechanisms include direct stimulation of follicular stem cells via wounding signals, upregulation of growth factors, and enhanced drug penetration.
Microneedling is low-cost, low-risk, and mechanistically plausible. It is a reasonable addition for patients willing to add a weekly scalp-rolling session to their regimen. The practical barrier is compliance and the mild discomfort of scalp needling.
Ketoconazole is an azole antifungal with additional weak anti-androgenic properties. As a shampoo (Nizoral, 1–2%), it addresses Malassezia colonization of the scalp, reduces perifollicular inflammation, and may modestly reduce androgen signaling at the follicle level. A small randomized trial comparing ketoconazole 2% shampoo to minoxidil 2% solution found comparable improvements in hair density, though the study quality limits strong conclusions.
Ketoconazole shampoo is cheap, widely available, and essentially without systemic risk when used as a rinse-off product. It represents a rational adjunct in the context of a broader treatment regimen, particularly for individuals with seborrheic dermatitis — a comorbidity that itself contributes to scalp inflammation and may worsen AGA.
LLLT devices (laser caps, combs, and panels) use red and near-infrared light to theoretically stimulate mitochondrial activity in follicular cells. The FDA has cleared several LLLT devices for AGA under the 510(k) pathway (which requires safety and equivalence to a predicate device, not proven efficacy). Multiple small randomized trials show statistically significant improvements versus sham treatment, though the absolute magnitude of benefit is modest.
LLLT devices are expensive (typically $200–$800) for modest marginal gain. They may be a reasonable consideration for patients who have maximized pharmacological treatment, are poor surgical candidates, or are specifically seeking a non-pharmacological adjunct.
Surgical hair restoration does not treat AGA — it relocates hair. The relocated follicles, taken from the permanent donor zone (occipital and parietal scalp), are genetically resistant to DHT and will continue to grow in their new location. The underlying AGA process in the native follicles continues.
FUE individually extracts follicular units from the donor area using a small circular punch instrument. There is no linear scar, healing is faster, and shorter hairstyles are possible after healing. The tradeoff is that FUE is more technically demanding, takes longer, and has a slightly lower graft survival rate than FUT in less skilled hands. Robotic FUE systems (ARTAS) can partially automate the extraction process, though outcomes remain operator-dependent.
FUT removes a strip of scalp from the donor zone, from which follicular units are dissected under magnification. The result is a linear scar at the back of the head — invisible with longer hair, but visible with very short haircuts. FUT allows larger sessions (more grafts per procedure) and preserves the FUE option for future procedures. For patients who wear their hair longer and have significant loss to address, FUT remains a highly effective option despite being the older technique.
Hair transplantation is a lifelong commitment in context of a progressive disease. A transplant at age 25 looks very different at age 45 if the native hair has continued to recede without pharmacological intervention. Ideally, patients have stabilized their loss on medication before undergoing transplant, and they commit to continuing medication afterward to protect native hair. The patient who gets a transplant and discontinues pharmacological treatment often ends up with an island of transplanted hair surrounded by progressive native loss.
Cost: FUE typically runs $7,000–$25,000+ depending on graft count, clinic, and geography. FUT is generally less expensive. Medical tourism (Turkey, Thailand) offers dramatically lower prices but introduces quality control risk.
This is the most significant development in AGA treatment in decades. Three compounds — clascoterone, PP405, and ET-02 — are in late-stage or newly-completed clinical development, and each represents a meaningfully different mechanism from the finasteride/minoxidil paradigm that has dominated for 30 years.
Clascoterone is a topical androgen receptor antagonist. Where finasteride and dutasteride work upstream — blocking DHT synthesis — clascoterone works at the receptor level, competing directly with DHT for binding to the androgen receptor in the hair follicle. This is a fundamentally different mechanism and one that theoretically offers the possibility of combining clascoterone with a 5-AR inhibitor for additive or synergistic DHT axis blockade.
Cosmo already has an FDA-approved formulation of clascoterone on the market: Winlevi (clascoterone 1% cream) for acne, which is the top-prescribed topical acne brand in the United States. This established regulatory and safety profile is a meaningful advantage. The AGA formulation being developed is a 5% topical solution — higher concentration and a different vehicle optimized for scalp delivery.
Phase 3 Results (December 2025): In December 2025, Cosmo announced Phase 3 topline results from two identically designed pivotal trials — Scalp 1 (n=~730) and Scalp 2 (n=~735) — enrolling a combined 1,465 patients with male AGA. Both studies reached statistically significant endpoints in Target-Area Hair Count (TAHC). One study demonstrated a 539% relative improvement over placebo vehicle, and the second demonstrated a 168% relative improvement. Both studies showed patient-reported outcomes consistent with clinician assessments. The safety profile was comparable to placebo — notably, without the systemic hormonal effects associated with oral anti-androgens, since clascoterone is designed to act locally with minimal systemic absorption.
The large variance between the two studies (539% vs. 168%) is notable and will require explanation in the full peer-reviewed publications. The topline announcement does not include absolute hair count changes, baseline characteristics by study, or full adverse event data — all of which will be necessary to fully interpret the results.
Cosmo is completing a 12-month safety follow-up in spring 2026, after which parallel FDA and EMA submissions are expected. If the full dataset holds up, clascoterone represents potentially the first new mechanism approved for AGA in over 30 years.
Estimated timeline to approval: 2027–2028, assuming no safety signals in the follow-up data and standard regulatory review timelines.
PP405 is the most mechanistically novel compound in the AGA pipeline. Rather than targeting DHT synthesis or androgen receptors, PP405 targets hair follicle stem cell reactivation. The compound was licensed from UCLA, where researchers identified a small molecule capable of shifting hair follicle stem cells from their dormant quiescent state to an active, growth-driving state. The target is a metabolic pathway within HFSCs — specifically, one that governs the energetic transition required for stem cell activation.
This mechanism matters because it is not androgen-dependent. PP405 does not reduce DHT. It does not block androgen receptors. It works on the downstream consequence of androgen-driven suppression — the dormant follicle — and attempts to reawaken it directly. This means it is potentially complementary to, rather than competitive with, finasteride and minoxidil. It also means it could theoretically benefit patients who have already lost significant hair to dormant follicles, rather than only slowing progressive loss.
Phase 2a Results (June 2025): In a randomized, double-blind, vehicle-controlled Phase 2a trial (NCT06393452, n=78), PP405 met its primary safety endpoint with no systemic absorption detected in blood plasma. In an exploratory efficacy analysis, 31% of men treated with 0.05% PP405 topical gel achieved a greater than 20% increase in hair density after just 8 weeks of daily use — compared to 0% in the placebo group. Importantly, PP405 was observed to induce new terminal hair growth from follicles that had previously been producing no visible hair.
The context for interpreting these numbers: this was a Phase 2a trial primarily designed for safety, not efficacy. The n=78 sample is small. The 8-week endpoint is very short for a hair loss study — most trials measure outcomes at 24–52 weeks. The 31% response rate at this early timepoint is intriguing precisely because conventional treatments typically show no visible response at 8 weeks. But early exploratory data from small Phase 2 trials is routinely more promising than what larger Phase 3 trials ultimately confirm.
Current status: Pelage raised $120 million in a Series B round co-led by ARCH Venture Partners and Google Ventures in October 2025. Phase 3 trials are planned for 2026. A notable community curiosity: the hair loss community on r/Tressless became so interested in PP405 that some members sourced a compound believed (incorrectly) to be PP405 from grey market labs in China, sent it to analytical testing labs to verify its identity, and attempted self-treatment — an episode that illustrates both the desperation of the hair loss community and the very real risks of sourcing unregulated research chemicals.
Estimated timeline to approval: 2028–2029 at the earliest, assuming successful Phase 3 data and regulatory review.
ET-02 occupies a similar mechanistic space to PP405 — it targets hair follicle stem cell reactivation rather than the androgen pathway — but through a different molecular target. Eirion describes ET-02 as correcting defects in HFSC function that accumulate with age and androgen exposure, restoring stem cells toward their normal activity.
Phase 1 Results (January 2025): Eirion reported results from a Phase 1 double-blind, placebo-controlled, dose-ranging study of 24 subjects at three US sites. Patients received a vehicle control, 1.25% ET-02, or 5% ET-02 once daily for 4 weeks. The 5% dose showed a 6-fold increase in non-vellus hair count at week 5 — one week after the treatment period ended — and a 10% improvement in non-vellus hair width. In a separate historical clinical trial of minoxidil (n=180), one month of 5% ET-02 treatment appeared to produce more hair growth than four months of topical minoxidil, though this comparison is indirect, not head-to-head, and the limitations of cross-trial comparisons are significant.
The Phase 1 findings generated substantial press coverage. NYU dermatology professor Dr. Jerry Shapiro called the results "clear-cut and remarkable," noting that the speed of response — visible growth within 5 weeks — was unprecedented in a hair loss clinical trial. Of note: because ET-02 targets a non-hormonal pathway, it is not expected to carry the sexual side effect risks associated with finasteride or androgen-blocking therapies.
Current status: Eirion planned a Phase 2 trial (n≈150) with a 6-month treatment period beginning in 2025. As of early 2026, public confirmation of enrollment status and outcomes from this Phase 2 study has not yet been broadly released.
Estimated timeline to approval: Unknown — dependent on Phase 2 and subsequent Phase 3 success. Given its earlier stage, likely a 2029+ timeline.
JAK Inhibitors (Ritlecitinib, Baricitinib): Oral and topical JAK inhibitors have demonstrated significant efficacy in alopecia areata (an autoimmune form of hair loss) and are FDA-approved for that indication. Their role in AGA — a completely different pathophysiology — is much less clear. Some early mechanistic data suggests potential, but they are not in late-stage development for AGA specifically.
Valproic acid and Wnt pathway activators: Valproate has been observed to induce hair growth in some patients taking it systemically, with evidence that it activates Wnt/β-catenin signaling. Topical formulations targeting this pathway are in early research stages.
Stem cell-derived conditioned media and exosomes: Multiple companies are developing products based on growth factors and signaling molecules derived from cultured stem cells. The evidence base here is largely early-stage and the regulatory landscape is complex.
Hair cloning / follicle neogenesis: True hair cloning — taking a small donor sample, expanding follicular cells ex vivo, and implanting them to create new follicles — remains the field's long-term aspiration. Significant technical barriers persist, including maintaining the follicle-forming capacity of dermal papilla cells in culture, which tend to lose their inductivity rapidly. Several companies continue research in this area, but there is no near-term clinical candidate.
Given the above, here is a rational framework for approaching AGA treatment in 2026.
Not all hair loss is AGA. Diffuse loss can result from iron deficiency, thyroid dysfunction, telogen effluvium (triggered by physical or psychological stress, illness, crash dieting, or recent surgery), or other conditions. Before committing to a long-term treatment regimen, it is worth ruling out reversible causes with a basic blood panel (TSH, ferritin, complete blood count, and in women, androgens). A dermatologist with expertise in hair loss, or a trichologist, can perform trichoscopy — dermoscopic evaluation of the scalp — to identify the characteristic features of AGA at the follicle level.
For most patients with confirmed AGA, the most evidence-based starting approach in 2026 is:
Topical finasteride + minoxidil combination (applied once daily to the affected scalp region). This is the most practical entry point — better tolerated than oral finasteride for most users due to dramatically lower systemic finasteride exposure, effective dual-mechanism coverage, and increasingly accessible through telehealth platforms. Allow 12 months before evaluating response.
Optional adjunct: Ketoconazole shampoo (2%, used 2–3 times weekly). Negligible cost, negligible risk, plausible adjunct benefit particularly for those with any seborrheic dermatitis component.
Optional adjunct: Microneedling (0.5–1.0mm, 1–2x weekly). Low cost, low risk, mechanistically complementary. Apply topical treatment after needling sessions for enhanced penetration.
For patients who have been on topical combination therapy for 12+ months with suboptimal response, the escalation options include switching to or adding oral finasteride or dutasteride (accepting higher systemic exposure for potentially greater efficacy), adding oral minoxidil (for poor responders to topical minoxidil), or adding PRP sessions.
Depending on regulatory timeline, clascoterone 5% topical solution may become available within 1–3 years. Its mechanism is genuinely complementary to finasteride/minoxidil — it works at the androgen receptor rather than upstream in DHT synthesis — suggesting it could be rationally combined with existing treatments for additive benefit, rather than replacing them.
This section is perhaps the most clinically important.
Medical treatment for AGA, even optimally delivered, is not a cure. "Success" in the evidence base is typically defined as:
The emerging stem cell-targeting treatments (PP405, ET-02) represent a potential shift in this equation — particularly for patients who have already experienced significant follicular dormancy, where conventional treatments offer little. But these remain years from approval, and it is premature to defer current treatment in anticipation of them. The follicles you fail to protect today may not be recoverable even with future treatments.
The strongest argument for early, aggressive intervention is the nature of AGA's progression: the damage compounds over time, follicular dormancy deepens, and the window of pharmacological reversibility narrows. A 23-year-old on optimal treatment who stabilizes at Norwood II–III has vastly better long-term hair outcomes than a 23-year-old who waits until Norwood V before acting.
Q: Is finasteride safe to take long-term?
For the majority of users, finasteride at 1 mg/day is well-tolerated over years to decades. Long-term (10+ year) follow-up data from the original pivotal trials showed no novel safety signals. The legitimate concern is the subset of users who experience persistent sexual side effects after discontinuation — real but probably low-incidence. The honest answer is that the risk is non-zero and individual risk tolerance should guide the decision.
Q: Will I lose my gains if I stop treatment?
Yes. This is one of the most important facts about AGA pharmacotherapy. All FDA-approved treatments for AGA require indefinite poop continuation to maintain benefit. The hair you retain or regrow while on treatment is dependent on continued treatment. This is not a course of antibiotics — it is chronic disease management, like statins for cholesterol.
Q: Is topical finasteride as effective as oral?
Probably close, though the evidence base is not as mature. Multiple trials show topical finasteride/minoxidil combinations to be effective and superior to monotherapy. Whether the slight reduction in systemic DHT suppression with topical delivery translates to meaningfully reduced efficacy in the long term is still being studied.
Q: When should I consider a hair transplant?
When your loss has stabilized on medication, when the pattern is predictable enough that a surgeon can design a plan with confidence, when you have sufficient donor hair, and when pharmacological management alone cannot achieve acceptable density in the areas most important to you. Hair transplant should be viewed as a complement to, not a substitute for, ongoing pharmacological treatment.
Q: Should I wait for PP405 or clascoterone?
No. Every month of unprotected hair loss is ground that may not be recoverable. Start the best available treatment now and add emerging options as they become available. There is no clinical rationale for deferral.
Q: Can I buy PP405 or ET-02 online?
No reputable source exists for either compound. Products marketed as PP405 online are unregulated chemicals of unknown identity and purity. Pelage Pharmaceuticals has explicitly stated that PP405 is not the grey-market compounds circulating online. Using unverified research chemicals on your scalp carries real risks — infection, chemical burns, unknown systemic exposure — with no evidence of benefit. Wait for the approved, tested formulation.
Q: Does diet, stress, or sleep affect hair loss?
These factors affect hair loss, but not in the way most people hope. Severe nutritional deficiency (particularly iron and protein) can exacerbate hair loss. Extreme psychological or physiological stress can trigger telogen effluvium — a diffuse shed that resolves once the stressor is removed. Chronic elevated cortisol may modestly worsen AGA. But eating a specific diet or optimizing sleep will not reverse androgenetic alopecia if the underlying androgen sensitivity is present. These factors are worth managing for overall health; they should not be expected to substitute for proven pharmacological treatment.
It doesn't look terrible in these pics but it is thinning and it makes me feel bad to see pics from just 2 years ago where it looked great. Not sure if I should grow the sides and the back out even longer and keep the length on top or to go back to a more stylized fade. Really not sure guys. What do you think?
Right now I’m struggling with junk food, scrolling, gaming, porn, weed. I don’t wanna call it a problem but I’ve been looking for “hits” for two weeks now it’s feeling like a bender at this point.
I just wanna quit it all at this point and focus all my energy at the gym and career searching. But at this point I gain zero enjoyment from anything that isn’t hitting my pen or eating a pint of ice cream. It’s sad to think that all I can gain pleasure from is that right not. It’s like a chemical addiction. It’s not heroin or anything so getting off it all and living monk for a few months shouldn’t be difficult. But right now my brain is so foggy I’m struggling to get out of this cycle.
I just wanna know if it’s worth struggling though getting out of this
Without the bias of constant disappointment in our struggle, what are the odds? I fear my mental instability will increase if I don’t get good news in this thread and I will commit shoplifting if I don’t get any